



Antibiotic Consumption in the Community in Ireland

Are we making any progress to improve appropriate antibiotic prescribing?

REPORT FOR
2012
April 2013

Comments from

Dr Nuala O Connor

*ICGP Clinical Lead
Health Care Associated
Infections and Antimicrobial
Drug Resistance*

Community Antibiotic Use-The Facts

- The rate for Quarter 4 of 2012 (1st October to 31st December) was 24.6 Defined Daily Doses per 1000 Inhabitants per Day
- Antibiotic use in the community in Ireland decreased in 2008 and 2009, however, antibiotic use increased again in 2012 to 22.9 DDD
- In comparison to other EU countries, antibiotic use in Ireland is mid-to-high
- Ireland has a proportionately higher use of co-amoxiclav and macrolides within the EU, and lower use of fluoroquinolones, though there is wide variation at county level
- Use of specific antibiotic groups, especially co-amoxiclav and related substances, has increased while other antibiotics quinolones and second generation cephalosporins, has decreased
- Antibiotic use is seasonal: the average winter usage has remained higher than summer usage

European Comparisons:

Antibiotic use in Ireland is mid-to-high compared with other EU countries






Fig 1: Total outpatient antibiotic use in Europe in 2010 expressed in DDD per 1000 inhabitants per day.

Generated from ESAC-Net data submitted to TESSy, The European Surveillance System on 2013-03-25; reflects the state of submissions in TESSy as of 2013-03-25 at 11:30. Finland: hospital sector data include consumption in remote primary health care centres and nursing homes, thus overestimating hospital consumption and underestimating community consumption compared to the other countries that report data from these sources as community consumption. Cyprus, Greece, Iceland provided only total care data.



European & Irish County Comparisons:



Quarterly Changes:

The underlying trend was generally rising but declined in 2008 and 2009, though has returned to previous levels




Fig 3: Total outpatient antibiotic use in Ireland from Quarter 1 of 2000 to Quarter 4 of 2012 expressed in DDD per 1000 inhabitants per day.

Monthly Changes:

Antibiotic use in 2012 is in line with rates for the last four years, though slightly higher and greater rise in November




Fig 4 : Total outpatient antibiotic use in Ireland by month from January 2008 to December 2012 expressed in DDD per 1000 inhabitants per day.

Yearly Changes in Cost:

Total ingredient cost increased slightly to €43M for 2012 compared to €42M in 2011




Fig 5: Total ingredient cost of outpatient antibiotic use in Ireland 2006 to 2012 in millions of Euro.

Latest Data- By antibiotic class

Table 1 : Total outpatient antibiotic use in Ireland for 2011 and 2012, and the last quarter of 2012 expressed in DDD per 1000 inhabitants per day.

	2011	Percent of 2011	2012	Percent of 2012	Percent Change 2011 to 2012	2012Q3	2011Q4	2012Q4	Percent Change 2011Q4 to 2012Q4
Penicillins	12.3	54.0%	12.5	54.6%	1.9% ▲	11.1	13.1	13.3	2.1%
Narrow spectrum penicillins	1.0	4.4%	1.0	4.4%	1.1%	1.0	1.0	1.0	-2.8%
Beta-lactamase resistant penicillins	1.0	4.6%	1.0	4.6%	-0.1%	1.2	1.0	1.0	-0.4%
Broad spectrum penicillins	3.6	15.7%	3.7	15.9%	2.3% ▲	3.2	3.8	3.8	-1.9%
Penicillin with beta-lactamase inhibitor	6.7	29.3%	6.8	29.7%	2.1% ▲	5.8	7.2	7.5	5.4%
Macrolides and related drugs	4.2	18.4%	4.2	18.2%	-0.7% ▼	3.4	4.7	4.7	-0.1%
Tetracyclines	2.8	12.3%	2.9	12.8%	4.6% ▲	2.8	2.9	3.0	3.9%
Cephalosporins and other beta-lactam drugs	1.2	5.3%	1.2	5.2%	-2.1% ▼	1.0	1.3	1.4	6.2%
First-generation cephalosporins	0.2	0.7%	0.2	0.8%	7.5%	0.2	0.2	0.2	8.4%
Second-generation cephalosporins	0.9	4.1%	0.9	4.0%	-3.3%	0.7	1.0	1.1	6.9%
Third-generation cephalosporins	0.1	0.5%	0.1	0.4%	-6.0% ▼	0.1	0.1	0.1	-4.3%
Quinolones	0.9	4.1%	0.9	3.8%	-6.6% ▼	0.9	1.0	0.9	-9.1%
Sulfonamides and Trimethoprim	1.2	5.2%	1.2	5.0%	-2.9% ▼	1.2	1.3	1.2	-3.7%
Other antibiotics	0.1	0.6%	0.1	0.5%	-24.6%	0.1	0.1	0.1	-22.2%
TOTAL	22.7	100.0%	22.9	100.0%	0.8% ▲	20.4	24.3	24.6	1.2%

Quarterly Changes - Pharmacological Subgroup:

Rate for penicillins and macrolides increased while quinolones and cephalosporin rates decreased




Fig 6: Antibiotic use in Ireland outpatient care from Q1 of 2003 to Q4 of 2012 expressed in DDD per 1000 inhabitants per day by pharmacological subgroup (ATC level 3).

Quarterly Changes – Penicillins:

Penicillin with beta-lactamase inhibitor (such as co-amoxiclav) use is increasing




Fig 7: Antibiotic use in Ireland outpatient care from Q1 of 2003 to Q4 of 2012 expressed in DDD per 1000 inhabitants per day by penicillin subgroup (ATC level 4).

Penicillin with enzyme inhibitor (such as co-amoxiclav) is not a first-line drug for the common conditions encountered in General Practice

Quarterly Changes – Cephalosporins:

Use of second generation cephalosporins decreased in 2008 to a new annual level




Fig 8: Antibiotic use in Ireland outpatient care from Q1 to 2003 to Q4 of 2012 expressed in DDD per 1000 inhabitants per day by cephalosporin subgroup (ATC level 4).

Seasonal Fluctuations – Counties, 2012




Fig 9: Seasonal variation of total antibiotic consumption (winter quarters over summer quarters expressed as percentage) in 2012 varied from 8% to 31% at county level and was 17% overall for Ireland.

2011 Census used for rate calculations.

Effects of Influenza:

Seasonal fluctuation with high winter peaks has remained strong over the years. Note: Modelled use takes into account periods of high influenza activity




Fig 10: Total outpatient antibiotic use in Ireland from January 2004 to December 2012 expressed in DDD per 1000 inhabitants per day.

Antibiotic Groups – Counties, 2012




Fig 11:

A. Penicillins

Consumption of penicillins (J01C) expressed in DDD per 1000 inhabitants and per day. E.g. Amoxillin or Co-amoxiclav

B. Macrolides

Consumption of macrolides, lincosamides and streptogramins (J01F) expressed in DDD per 1000 inhabitants and per day. E.g. Clarithromycin

C. Cephalosporins

Consumption of cephalosporins (J01D) expressed in DDD per 1000 inhabitants and per day. E.g. Cefaclor

D. Quinolones

Consumption of quinolones (J01M) expressed in DDD per 1000 inhabitants and per day. E.g. Ciprofloxacin

For figures 11 and 12, the same type of scheme as the one in fig 1 is used for eight ECDC (ESAC-Net) quality indicators to show variation in Irish counties scaled against ECDC 2010 data. The scale has been graduated to show greater contrast between counties.

Antibiotic Groups – Counties, 2012




Fig 12:

E. Narrow Spec Penicillins

Consumption of beta-lactamase sensitive penicillins (J01CE) expressed as percentage of the total consumption of antibacterials for systemic use (J01). E.g. Phenoxymethylpenicillin. ^This measure is inverted

F. Penicillins with Enzyme Inhib.

Consumption of combination of penicillins, including beta-lactamase inhibitor (J01CR) expressed as percentage of the total consumption of antibacterials for systemic use (J01). E.g. Co-amoxiclav


G. Third Gen Cephalosporins

Consumption of third and fourth generation of cephalosporins (J01(DD+DE)) expressed as percentage of the total consumption of antibacterials for systemic use (J01). E.g. Cefixime. No 4th gen ceph use in Ireland

H. Broad V Narrow

Ratio of the consumption of broad (J01(CR+DC+DD+(F-FA01))) to the consumption of narrow spectrum penicillins, cephalosporins and macrolides (J01(CE+DB+FA01))

Antibiotic Groups – Counties, 2012



Positive changes v Where we can improve

	Yearly Change (2011 to 2012)	Recent Trend	Compared to Europe	County-Level Variation	Seasonality	
Penicillins (e.g. amoxicillin, co-amoxiclav)	Up	Up	Mid-high	Mid	High	
<i>Penicillin with beta-lactamase inhibitor (e.g. co-amoxiclav)</i>	Up	Up	Mid-high	High	High	
Macrolides and related drugs (e.g. clarithromycin)	Down	Up	High	Mid	High	
Tetracyclines (e.g. doxycycline, minocycline)	Up	Up	Mid	Mid	Low	
Cephalosporins and other beta-lactam drugs (e.g. cefaclor, cefixime)	Down	Down	Low	Mid	High	
<i>Third-generation cephalosporins (e.g. cefixime)</i>	Down	Slightly up	Mid	High	Low	
Quinolones (e.g. ciprofloxacin)	Down	Flat	Very low	High	Low	
Overall Antibiotic Use	Slightly up	Up	Mid-high	High	High	

Observations and tips on appropriate prescribing

- The **low** level use in some broad-spectrum drugs is encouraging, in particular
 - Quinolones (such as ciprofloxacin), cephalosporins and specifically 3rd generation cephalosporins (such as cefixime)

▶ Continue usage at low levels
- The **high** level use in other broad-spectrum is discouraging, in particular
 - Penicillin with enzyme inhibitor (such as co-amoxiclav)

▶ Use narrow-spectrum penicillins where possible
- The **high** degree of seasonal variation is discouraging

▶ Excess use in winter should be curtailed
- The **high** degree in county-level variation is discouraging

▶ Greater standardisation in prescribing is advised

“Keeping antibiotics effective for future generations is everyone's responsibility”

Every time you prescribe you need to ask yourself:

- Is this antibiotic prescription necessary?
- Would a delayed prescription suffice?
- Is it the correct/narrow spectrum antibiotic for the infection I am treating?
- Is the dose/duration right for the patient in front of me?
- Have I checked www.antibioticprescribing.ie ?

Dr Nuala O Connor

ICGP Clinical Lead

Health Care Associated Infections and Antimicrobial Drug Resistance

Methods

- Irish antibiotic sales data were from IMS Health, a pharmaceutical market research company. This dataset contains regional, monthly wholesaler to retail pharmacy sales data from over 95% of the wholesalers and manufacturers in Ireland.
- Consumption is measured in Defined Daily Dose (DDD), which is the assumed average maintenance dose per day for a drug used for its main indication in adults. The current WHO Anatomical Therapeutic Chemical index was used to classify the antibiotics.
- Rates were calculated in DDD per 1000 inhabitants per day (DID) for the outpatient antibiotic consumption data. Updated population size estimates were obtained from the Central Statistics Office and used to calculate monthly and quarterly rates. Values for 2012 were projected from census data since 1996.
- Monthly expected usage values were calculated from time-series data using an ARIMA transfer model in which the influenza-like illness level over the national threshold was used a binary event variable along with a point for Jan 2010 when drug sales were impacted by severe weather conditions. The underlying trend on the quarterly graph was derived via seasonal decomposition.

Further information

- See: [Guidelines on HPSC Website](#)
 - Antibiotic prescribing guidelines in primary care
 - Also www.antibioticprescribing.ie
 - Diagnosis and management of urinary tract infection in residents of long term care facilities
 - Hand hygiene, MRSA, *C. difficile* and many other guidelines
- European Surveillance of Antimicrobial Consumption Network ([ESAC-Net](#))
- WHO Collaborating Centre for Drug Statistics Methodology (for [ATC-DDD method](#))

INCREASE IN INVASIVE GROUP A STREPTOCOCCAL INFECTIONS: ADVICE FOR GENERAL PRACTITIONERS /OUT OF HOURS SERVICES/EMERGENCY DEPARTMENTS

There has been a significant increase in invasive Group A *Streptococcus* (iGAS) cases notified to HPSC in the first quarter of 2013, similar to the increase noted in 2012. Of note, there has been an increase in the number of paediatric cases reported in the first quarter of 2013. Six iGAS-associated deaths were reported during the first 16 weeks of 2013.

WHAT IS INVASIVE GROUP A STREP (IGAS)?

iGAS infections are acute, frequently life-threatening, infections ranging from bacteraemia (bloodstream infection), cellulitis and pneumonia to meningitis, puerperal sepsis and septic arthritis. Two of the most severe forms of iGAS are necrotizing fasciitis and Streptococcal Toxic Shock Syndrome (STSS).

WHAT SHOULD ALERT YOU TO POSSIBLE IGAS INFECTION ?

Watch out for patients with pharyngitis, cellulitis, impetigo who seem sicker than you would normally expect

1: SUSPECTED INVASIVE GROUP A STREPTOCOCCUS INFECTION

- Patients with symptoms or physical findings consistent with iGAS infection should be **immediately referred to hospital**. These may include:
 - High fever, chills, rigors, sweats, myalgia and localised pain (suggesting septicaemia and invasive bacterial infection)
 - Abrupt onset of fever and severe pain, which may be early findings in STSS
 - In patients with cellulitis or other skin/soft tissue infections, pain and tenderness out of proportion to the appearance of the area, oedema, erythema, skin anaesthesia or bullae formation are suggestive of necrotizing fasciitis

2: PHARYNGITIS: ALL INVASIVE GROUP STREP IS SENSITIVE TO PHENOXYMETHYLPENICILLIN

- Phenoxyethylpenicillin is the drug of choice for treating streptococcal pharyngitis (clarithromycin if documented penicillin allergy)
- Patients who have a low to moderate risk of Group A streptococcal infection, based on clinical findings, should have a throat swab taken and antibiotic therapy commenced if the culture is positive for Group A *Streptococcus*
- Most pharyngitis seen in the community is viral
- Use modified Centor criteria below to determine risk of Group A strep infection and if suspected ensure you prescribe the right dose of phenoxyethylpenicillin (calvopen, kopen) for the right duration for the patient you are treating .
- Treatment failures arise from prescribing too little antibiotic for too short a time .
- Pharyngitis should be managed in line with the Irish national guidelines for antibiotic prescribing in primary care (www.antibioticprescribing.ie)

STREP THROAT SCORE (MODIFIED CENTOR CRITERIA)

Criteria	Points
Temperature >38°	1
No cough	1
Tender anterior cervical adenopathy	1
Tonsillar swelling or exudates	1
Age 3-14 years	1
Age 15-44 years	0
Age >44 years	-1

Score	Probability of GAS infection	Suggested management
≥4	51-53%	Treat with penicillin (clarythromycin, if documented penicillin allergy)
3	28-35%	Send throat swab and treat with penicillin if culture positive (clarythromycin, if documented penicillin allergy)
2	11-17%	
1	5-10%	Symptomatic treatment only
≤0	1-2.5%	

3: IMPETIGO

- Although impetigo is often caused by Group A *Streptococcus*, the most common causative organism is *Staph aureus*
- Flucloxacillin (or clarythromycin if documented penicillin allergy) is the drug of choice, and has activity against Group A *Streptococcus* as well as *Staph aureus*
- Avoid the use of topical antibiotic therapy while there is an ongoing increase in GAS infections
- Details of treatment recommendations are included in the Irish national guidelines for antibiotic prescribing in primary care (www.antibioticprescribing.ie)

4: CELLULITIS

- Mild to moderate cellulitis can be treated with flucloxacillin (or clarythromycin, or clindamycin, if documented penicillin allergy)
 - Co-amoxiclav for facial cellulitis
- If persistent fever, unwell, or failing to respond to oral therapy, refer to hospital for intravenous therapy
- If rapidly spreading cellulitis, or any findings associated with necrotizing fasciitis or STSS, refer urgently to hospital
- Details of treatment recommendations are included in the Irish national guidelines for antibiotic prescribing in primary care (www.antibioticprescribing.ie)

Dr Robert Cunney, Consultant Microbiologist, Health Protection Surveillance Centre

Dr Niamh O' Sullivan, Consultant Microbiologist, Our Lady's Children's Hospital, Crumlin

Dr Nuala O'Connor, General Practitioner, ICGP Clinical Lead for HCAI/AMR